Archive · 19 Dec 2025
Sudeep Pharma Q2 Results: Revenue Up, Profit Down
Sudeep Pharma, a company that makes medicines, recently shared its financial results for the second quarter.
The company made more money from selling its products, with revenue increasing by 9.3% compared to the same time last year.
However, the company's profit decreased by 6.15%, and its earnings before interest, taxes, depreciation, and amortization (EBITDA) also dropped by 11.2%.
This means the company is making more sales but keeping less of that money as profit.
Sudeep Pharma recently started selling shares to the public, and its initial public offering (IPO) was very popular, with many people wanting to buy shares.
The company's shares are now trading on the stock market, and on the day the results were announced, the share price went up by 1.46%.
Sudeep Pharma's net profit fell 6.15% year-on-year to ₹45.8 crore.
Revenue rose 9.3% year-on-year to ₹162.7 crore.
EBITDA declined 11.2% to ₹55.5 crore, with margins narrowing to 34.1% from 42.7%.
The company's IPO was subscribed 93.72 times and raised ₹895 crore.
Shares of Sudeep Pharma ended higher on December 19, by 1.46% at ₹684 on the NSE.
- Who
- Sudeep Pharma, a Vadodara-based pharmaceutical company
- What
- Reported Q2 financial results showing mixed performance
- When
- December 19, 2023
- Where
- Vadodara, India
- Why
- To update investors and stakeholders on the company's financial performance
- Net Profit
- ₹45.8 crore (down 6.15% YoY)
- Revenue
- ₹162.7 crore (up 9.3% YoY)
- EBITDA
- ₹55.5 crore (down 11.2% YoY)
- EBITDA Margin
- 34.1% (down from 42.7%)
- IPO Size
- ₹895 crore
- IPO Subscription
- 93.72 times
- Listing Date
- November 28
- Current Share Price
- ₹684 (as of December 19)